Regencell Bioscience Holdings Limited
RGC
Rangering i aksjer
#3382
Regencell Bioscience Holdings Limited is a biotechnology firm specializing in... Regencell Bioscience Holdings Limited is a biotechnology firm specializing in Traditional Chinese Medicine (TCM). Its core activities revolve around the research, development, and market introduction of TCM solutions specifically designed to address neurocognitive disorders and related degeneration. The company places a particular emphasis on conditions such as attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). Established in 2014, Regencell Bioscience maintains its primary office in Causeway Bay, Hong Kong.
Aksjekurs
$10.41
Sist synkronisert: 2026-10-20
Markedsverdi
$5.16B
Endring (1 dag)
3.56%
Endring (1 år)
-35.07%
Land
HK
Handel Regencell Bioscience Holdings Limited (RGC)
Kategori
Healthcare
P/B-forhold for Regencell Bioscience Holdings Limited (RGC)
P/B-forhold per October 2026 TTM: 300.54
Ifølge Regencell Bioscience Holdings Limited sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 300.54. Ved slutten av 2024 hadde selskapet et P/B-forhold på 5.08.
P/B-historikk for Regencell Bioscience Holdings Limited fra 2019 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 300.54 | -82.66% |
| 2025 | 1.73K | 34,010.49% |
| 2024 | 5.08 | -79.61% |
| 2023 | 24.92 | -5.54% |
| 2022 | 26.38 | -179.45% |
| 2021 | -33.21 | -33.69% |
| 2020 | -50.08 | -30.65% |
| 2019 | -72.20 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -98.32% |
IN
|
